TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00221429
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lithium
Study: NCT00221429
Drug: sodium divalproex
Normalized name: Divalproex Sodium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depakote
Study: NCT00456794
Drug: Istradefylline (KW-6002)
Normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00797485
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02487277
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02487277
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00329134
Drug: Administration of quinine sulphate taste-masked pellets
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01712217
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
Study: NCT02452112
Drug: 5% Lidocaine patch
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% Lidocaine patch to be placed on the site of pain
Study: NCT00571688
Drug: Risperdal (risperidone) Consta
Normalized name: risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperdal Consta (TM) will be administered every 2 weeks by deep intramuscular (IM) gluteal injection, by a trained health care professional. Injections will alternate between the two buttocks. The initial dose will be 25 mg IM every 2 weeks. A minimum dose of 25 mg. every 2 weeks will be maintained. At the clinician's discretion, the dose may be advanced to 37.5 mg. or 50 mg. In addition, the dose will be raised to 37.5 mg. or 50 mg. if the following conditions remain: (1) Young Mania Rating Scale (YMRS) score \> 12; or (2) Evidence of impending relapse; and no dose limiting side effect. If the 25 mg. dose is not tolerated, the dose can be held temporarily; however, attempts will be made to achieve and maintain the dose at 25 mg. (or higher) until the end of the study period.
Study: NCT04372342
Drug: nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalbuphine hydrochloride has strong analgesic effect, quick effect and long time by stimulating receptor, and has partial antagonistic effect on the receptor, so the incidence of respiratory depression is low in theory.
Study: NCT00030615
Drug: decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04584853
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib used in combination with standard Endocrine Therapy for 2 years from randomisation
Study: NCT02190747
Drug: Palovarotene
Normalized name: palovarotene
DrugBank: Palovarotene (DB05467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.
Study: NCT01612377
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral QD Prednisone 5mg
Study: NCT01612377
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, QD prednisone 7.5mg
Study: NCT00881361
Drug: systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01926847
Drug: Riociguat (Adempas, BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01034878
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib will be administered orally at a dose of 50 mg once daily, in six weeks cycles consisting of 4 weeks of treatment followed by 2 weeks without treatment.
Study: NCT01508494
Drug: Galantamine
Normalized name: Galantamine
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 mg galantamine daily P/O
Study: NCT02356146
Drug: Tacrolimus C12
Normalized name: C12:0
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04561245
Drug: ALT-801
Normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected subcutaneously (SC)
Study: NCT04315480
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single intravenous administration 8mg/Kg
Study: NCT03792451
Drug: Pegvaliase
Normalized name: PEGVALIASE
DrugBank: Pegvaliase (DB12839)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treated with pegvaliase for one or more years or followed an unrestricted diet for 6 or more months while being treated with pegvaliase.
Study: NCT03895112
Drug: AVID200
Normalized name: Tgf-beta 1/3 inhibitor avid200
DrugBank: AVID-200 (DB18454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose cohorts of 21-day cycles
Study: NCT02651792
Drug: ketamine- propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg x kg(-1) ketamine + 1.2 mg x kg(-1) propofol.
Study: NCT02651792
Drug: pethidine- propofol
Normalized name: pethidine
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
Study: NCT01103778
Drug: Bortezomib (Velcade®)
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).
Study: NCT03067129
Drug: Glecaprevir/Pibrentasvir Adult Formulation
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Co-formulated film-coated tablet (100 mg/40 mg)
Study: NCT03067129
Drug: Glecaprevir + Pibrentasvir Pediatric Formulation
Normalized name: glecaprevir / pibrentasvir
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Film-coated pellets/granules (15.67%/8.25%) administered by mixing with a small amount (1-2 teaspoons) of a soft food vehicle, such as hazelnut spread, Greek yogurt, or peanut butter.
Study: NCT00397176
Drug: desvenlafaxine succinate sustained release (DVS SR)
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00049218
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00049218
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00430963
Drug: IncobotulinumtoxinA (Xeomin) (20 Units)
Normalized name: incobotulinumtoxinA 100 UNT [Xeomin]
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT00783172
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2, IV (in the vein) over 30 minutes after treatment with OGF; first cycle is consecutive seven weeks and one week off; subsequent cycles are three weeks on and one week off.
Study: NCT01978509
Drug: Low volume prep (Prepopik)
Normalized name: low-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
Study: NCT01978509
Drug: High volume prep (Golytely)
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
Study: NCT02293356
Drug: Nimotuzumab Injection
Normalized name: inotuzumab ozogamicin Injection
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.
Study: NCT00091026
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00091026
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01896388
Drug: Ifenprodil Tartrate
Normalized name: ifenprodil tartrate
DrugBank: Ifenprodil (DB08954)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03002103
Drug: EndoTAG-1
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03002103
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03002103
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00217516
Drug: selenium
Normalized name: Selenium
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT02294006
Drug: Everolimus plus Octreotide LAR plus Metformin
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Everolimus plus Octreotide LAR plus Metformin
Study: NCT04782037
Drug: L-Methylfolate Calcium
Normalized name: L-Methylfolate Calcium
DrugBank: Levomefolic acid (DB11256)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid is one of the water-soluble B vitamins, which is synthetically-produced and found in fortified foods and supplements. It is essential for the synthesis and repair of DNA and RNA and metabolism of amino acids which are required for cell division. There is damage to the intestinal mucosa in most diarrhea cases; therefore, the role of folic acid has been studied as adjuvant therapy for diarrhea since folic acid plays an important role in the synthesis of DNA especially in rapidly regenerating cells.
Study: NCT00378755
Drug: velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01588353
Drug: Collagenase Clostridium Histolyticum
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
Study: NCT01700985
Drug: 122-0551
Normalized name: MSX-122
DrugBank: MSX-122 (DB12715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied twice daily for two weeks
Study: NCT01158729
Drug: Antithrombin (Recombinant)
Normalized name: Antithrombin (recombinant)
DrugBank: Antithrombin Alfa (DB11166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of antithrombin (recombinant) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: ATIII dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
Study: NCT00033033
Drug: Reserpine
Normalized name: Reserpine
DrugBank: Reserpine (DB00206)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00141700
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02790671
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg itraconazole
Study: NCT01788982
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib should be administered orally at a dose of 200 mg twice daily.
Study: NCT00461578
Drug: Chlorproguanil-dapsone + artesunate
Normalized name: Artesunate
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02180217
Drug: osilodrostat
Normalized name: osilodrostat
DrugBank: Osilodrostat (DB11837)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osilodrostat comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat was 30 mg bid.
Study: NCT04141553
Drug: Diltiazem Injection
Normalized name: diltiazem Injection
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomization to one of to active comparator groups
Study: NCT02595840
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02595840
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02411526
Drug: ZX003 (Risperidone-SABER®)
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ZX003 administered as a SC injection
Study: NCT02411526
Drug: Risperdal Consta
Normalized name: RisperDAL Consta
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperdal Consta administered as a IM injection
Study: NCT02411526
Drug: Oral Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
Study: NCT02807363
Drug: Leuprolide Oral Tablet 4-mg QD
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg Leuprolide oral tablet once daily for 28 consecutive days.
Study: NCT02807363
Drug: Leuprolide Oral Tablet 4-mg BID
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg Leuprolide oral tablet twice daily for 28 consecutive days.
Study: NCT02807363
Drug: Leuprolide Depot
Normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg intramuscular depot injection
Study: NCT02807363
Drug: Leuprolide Oral Tablet 10-mg BID
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg Leuprolide oral tablet twice daily for 28 consecutive days.
Study: NCT00744016
Drug: Granulated mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning
Study: NCT01195363
Drug: quetiapine SR
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine SR, dose range 200-600mg, each night QHS for 6mos
Study: NCT01195363
Drug: quetiapine sr placebo
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
Study: NCT02188719
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.
Study: NCT02188719
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~* TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~* EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF
Study: NCT02188719
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.
Study: NCT02188719
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.
Study: NCT02188719
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 25-50mg of diphenhydramine will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
Study: NCT02188719
Drug: Anti-Infective Prophylaxis
Normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir and/or oral Valcyte will be administered for the prophylaxis of cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) for at least six months after liver transplantation.
Study: NCT01214941
Drug: Ticlopidine
Normalized name: Ticlopidine
DrugBank: Ticlopidine (DB00208)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will be given orally ticlopidine 250mg twice a day for 5 days prior to the study.
Study: NCT01214941
Drug: Ticlopidine and itraconazole
DrugBank: Ticlopidine (DB00208)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will be given orally ticlopidine 250mg twice a day and itraconazole 200mg as a single daily dose for 5 days prior to the study.
Study: NCT02726113
Drug: cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: softgels 4000 IU daily for approximately two months prior to surgery (prostatectomy).
Study: NCT02058485
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam was calculated by actual body weight of patients that had been diluted with saline to 40 ml. It was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.025 mg.kg-1
Study: NCT02058485
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine was calculated by actual body weight of patients that had been diluted with saline to 40 ml. Dexmedetomidine was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.5 µg.kg-1
Study: NCT01578785
Drug: Glatiramer Acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate 20mg in 0.5ml for subcutaneous injection in a pre-filled syringe (PFS) is administered daily. Each PFS also contains 20mg mannitol dissolved in water for injection.
Study: NCT00966693
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00966693
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00966693
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00255294
Drug: Cellulose sulfate vaginal gel
Normalized name: cellulose sulfate
DrugBank: Sodium cellulose phosphate (DB06776)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02697630
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months
Study: NCT02697630
Drug: Entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months
Study: NCT01273389
Drug: CNTO 136
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.
Study: NCT04326023
Drug: PARP Inhibitors
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: olaparib, rucaparib, niraparib, talazoparib, veliparib
Study: NCT00377429
Drug: catumaxomab
Normalized name: catumaxomab
DrugBank: Catumaxomab (DB06607)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catumaxomab administered as four 3-hour, constant-rate, intraperitoneal (IP) infusions of 10, 20, 50, 150 microgram (mcg).
Study: NCT02013089
Drug: Erlotinib or Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150mg talbet or Gefitinib 250 mg tablet per day for patients with EGFR gene alternation
Study: NCT02013089
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 10 mg orally once daily every day for patients with mTOR gene alternation
Study: NCT02013089
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib 400 mg tablet orally per day for patietns with KIT, PDGFR, ABL gene alternation
Study: NCT05396898
Drug: LCP-tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylaxis of transplant rejection in liver and kidney allograft recipients
Study: NCT02013089
Drug: Sorafenib or Sunitinib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day with or without food for patients with VEGFR, KIT, RAF gene alternation
Study: NCT02013089
Drug: Vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vandetanib 300 mg orally once daily for patients with RET gene fusion.